Skip to search formSkip to main contentSkip to account menu

Anti-CD19/CD28/CD3zeta CAR Gammaretroviral Vector-transduced Autologous T Lymphocytes KTE-C19

Known as: KTE-C19, KTE-C19 CAR 
A preparation of autologous peripheral blood T-lymphocytes (PBTL) that have been transduced with a gammaretoviral vector expressing a chimeric… 
National Institutes of Health

Related topics

Related topics

5 relations
Antigen SensitizationCytotoxic T-LymphocytesNCIt Antineoplastic Agent TerminologyT-Cell Activation

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
End of phase I results of ZUMA-3, a phase 1/2 study of KTE-X19, anti-CD19 chimeric antigen receptor (CAR) T cell therapy, in adult patients (pts) with relapsed/refractory (R/R) acute lymphoblastic…
7006 Background: KTE-X19 is an autologous anti-CD19 CAR T cell therapy under investigation for adult R/R ALL. In an interim… 
Review
2019
Review
2019
KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) With Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Results of the Phase 2 ZUMA-2 Study
Background: Outcomes with salvage regimens in pts with MCL who progress after Bruton tyrosine kinase inhibitor (BTKi) therapy… 
Review
2018
Review
2018
Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL
Abstract The development of clinically functional chimeric antigen receptor (CAR) T cell therapy is the culmination of multiple… 
Review
2017
Review
2017
An interim analysis of the ZUMA-1 study of KTE-C19 in refractory, aggressive non-Hodgkin lymphoma.
SN The standard frontline therapy for diffuse large B-cell lymphoma (DLBCL) is chemoimmunotherapy with rituximab plus… 
2017
2017
Abstract CT019: Primary results from ZUMA-1: a pivotal trial of axicabtagene ciloleucel (axicel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (NHL)
Introduction: Outcomes for pts with refractory aggressive NHL are poor with current therapies (Crump, ASCO 2016). Results from… 
2016
2016
Production of Anti-CD19 CAR T Cells for ZUMA-3 and -4: Phase 1/2 Multicenter Studies Evaluating KTE-C19 in Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (R/R ALL)
Introduction: ZUMA-3 and -4 (NCT02614066 and NCT02625480) are ongoing phase 1-2 multicenter trials evaluating KTE-C19, a CD28/CD3… 
2016
2016
A Phase 2 Multicenter Trial of KTE-C19 (anti-CD19 CAR T Cells) in Patients With Chemorefractory Primary Mediastinal B-Cell Lymphoma (PMBCL) and Transformed Follicular Lymphoma (TFL): Interim Results…
Background: ZUMA-1 is a phase 1-2 multicenter, open-label study evaluating the safety and efficacy of KTE-C19 in patients with… 
2010
2010
On the stability of the thermal Comptonization index in neutron star low-mass X-ray binaries in their different spectral states
Context. Most of the spectra of neutron star low-mass X-ray binaries (NS LMXBs), whether they are persistent or transient, are… 
2005
2005
Taiwankadsurins A, B, and C, three new C19 homolignans from Kadsura philippinensis.
[structures: see text] Three novel C19 homolignans, designated taiwankadsurins A (1), B (2), and C (3), were isolated from the… 
Highly Cited
2001
Highly Cited
2001
Mode of action, purification and amino acid sequence of plantaricin C19, an anti-Listeria bacteriocin produced by Lactobacillus plantarum C19.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)